Publications by authors named "Darryl Sleep"

Claim this Profile
E
Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Anne C Goldberg, Vera Bittner, Carl J Pepine, Maureen T Kelly, Kamlesh Thakker, Darryl J Sleep

Am J Cardiol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Peter H Jones, Anne C Goldberg, Howard R Knapp, Maureen T Kelly, Carolyn M Setze, Darryl J Sleep

Am Heart J· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Harold E Bays, Eli M Roth, James M McKenney, Maureen T Kelly, Kamlesh M Thakker, Darryl J Sleep

Diabetes Care· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Tong Zhu, Jean-Claude Ansquer, Maureen T Kelly, Darryl J Sleep, Rajendra S Pradhan

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Peter H Jones, Kenneth Cusi, Michael H Davidson, Maureen T Kelly, Carolyn M Setze, Darryl J Sleep

Am J Cardiovasc Drugs· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Mark S Kipnes, Eli M Roth, James M Rhyne, Carolyn M Setze, Aditya Lele, Darryl J Sleep

Clin Drug Investig· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Peter H Jones, Michael H Davidson, Moti L Kashyap, Maureen T Kelly, Susan M Buttler, Darryl J Sleep

Atherosclerosis· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.
Peter H Jones, Michael H Davidson, Anne C Goldberg, Carl J Pepine, Maureen T Kelly, Darryl J Sleep

J Clin Lipidol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Peter H Jones, Harold E Bays, Michael H Davidson, Maureen T Kelly, Susan M Buttler, Darryl J Sleep

Clin Drug Investig· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Anne C Goldberg, Harold E Bays, Christie M Ballantyne, Maureen T Kelly, Susan M Buttler, Darryl J Sleep

Am J Cardiol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Tong Zhu, Walid M Awni, Balakrishna Hosmane, Maureen T Kelly, Darryl J Sleep

J Clin Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Syed M Mohiuddin, Carl J Pepine, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep

Am Heart J· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.
Harold E Bays, Peter H Jones, Syed M Mohiuddin, Maureen T Kelly, Hsiaoming Sun, Darryl J Sleep

J Clin Lipidol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Joel B Nelson, William Love, Joseph L Chin, Fred Saad, Claude C Schulman, Darryl J Sleep

Cancer· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Andrew J Armstrong, Patricia Creel, James Turnbull, Cassandra Moore, Tracy A Jaffe, Darryl Sleep

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Michael A Carducci, Fred Saad, Per-Anders Abrahamsson, David P Dearnaley, Claude C Schulman, Darryl J Sleep

Cancer· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
Eric Q Wu, Parvez Mulani, Max H Farrell, Darryl Sleep

Value Health· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.
Patrick W Sullivan, Parvez M Mulani, Mayer Fishman, Darryl Sleep

Qual Life Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual effects of rifampin on the pharmacokinetics of atrasentan.
Hao Xiong, Robert A Carr, Charles S Locke, David A Katz, Ramanuj Achari, Darryl J Sleep

J Clin Pharmacol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer.
Patrick W Sullivan, Joel B Nelson, Parvez M Mulani, Darryl Sleep

Qual Life Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and in vivo evaluation of a PET radioligand for imaging the endothelin-A receptor.
William B Mathews, Tamas G Zober, Hayden T Ravert, Ursula Scheffel, John Hilton, Darryl Sleep

Nucl Med Biol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction.
Jörn H Hagemann, Georg Berding, Sven Bergh, Darryl J Sleep, Wolfram H Knapp

Eur Urol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis